

Supplement Table 1. ACA expansion and non-expansion states

Main Analysis

Expansion States: AZ, AR, CA, CO, CT, DE, HI, IL, IA, KY, MD, MA, MI, MN, NH, NV, NJ, NM, NY, ND, OH, OR, RI, VT, WA, WV, DC

Non-Expansion States: AL, AK, FL, GA, IN, ID, KS, LA, ME, MS, MO, MT, NE, NC, OK, PA, SC, SD, TN, TX, UT, VA, WI, WY

Sensitivity Analysis

Expansion States: AZ, AR, CO, DE, HI, IL, IA, KY, MD, MA, MI, NH, NV, NM, NY, ND, OH, OR, RI, VT, WV


Non-Expansion States: AL, FL, GA, ID, KS, ME, MS, MO, NE, NC, OK, SC, SD, TN, TX, UT, VA, WI, WY

Source: Henry J. Kaiser Family Foundation. Status of state action on the Medicaid expansion decision [Internet]. San Francisco (CA): Available from: <https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act>

Supplement Table 2. Relative change in number of Medicaid patients treated with buprenorphine in Medicaid expansion and non-expansion states before and after expansion


	Medicaid Expansion States			Medicaid Non-Expansion States			
	Slope in quarterly number of patients treated with buprenorphine in thousands (95% CI)			Slope in quarterly number of patients treated with buprenorphine in thousands (95% CI)			
Groups	Pre-Expansion	Post-Expansion	Change	Pre-Expansion	Post-Expansion	Change	Difference-in-Differences <i>P</i>
	(2012-2013)	(2014-2018)		(2012-2013)	(2014-2018)		
Total	-0.39 (-1.52, 0.74)	2.75 (2.31, 3.19)	59.83 (32.09, 87.58)	-0.26 (-0.81, 0.30)	0.64 (0.36, 0.91)	16.73 (3.09, 30.36)	<.001
Men	-0.17 (-0.07, 0.40)	1.51 (1.30, 1.71)	32.11 (18.27, 45.94)	-0.14 (-0.34, 0.07)	0.26 (0.16, 0.37)	7.45 (2.40, 12.50)	<.001
Women	-0.21 (-0.79, 0.37)	1.24 (1.00, 1.48)	27.52 (13.26, 41.79)	-0.12 (-0.48, 0.23)	0.37 (0.20, 0.54)	9.25 (0.47, 18.02)	<.001
Age, years							
16-25	-0.05 (-0.15, 0.05)	0.06 (0.03, 0.09)	2.27 (-0.11, 4.65)	-0.04 (-0.13, 0.05)	-0.02 (-0.05, 0.00)	0.11 (-2.04, 2.27)	<.001
25-34	-0.14 (-0.57, 0.29)	1.07 (0.90, 1.23)	23.09 (12.63, 33.54)	-0.16 (-0.41, 0.08)	0.19 (0.09, 0.30)	6.59 (0.59, 12.60)	<.001
35-44	-0.18 (-0.68, 0.32)	0.89 (0.69, 1.09)	20.60 (8.34, 32.86)	-0.06 (-0.27, 0.16)	0.24 (0.15, 0.33)	6.02 (0.74, 11.30)	<.001
45-54	-0.05 (-0.22, 0.13)	0.44 (0.39, 0.49)	9.15 (4.98, 13.33)	-0.02 (-0.11, 0.06)	0.11 (0.07, 0.15)	2.58 (0.50, 4.66)	<.001
55-80	0.00 (-0.11, 0.11)	0.27 (0.24, 0.30)	5.12 (2.45, 7.80)	0.00 (-0.06, 0.05)	0.08 (0.05, 0.11)	1.62 (-0.20, 3.04)	<.001
Data source 2012-2018 IQVIA LRx.							

Supplement Figure 1: Mean quarterly percentage of buprenorphine prescriptions paid for by Medicaid in expansion and non-expansion states, 2012-18




Data Source: 2012-2018 IQVIA LRx. Vertical line denotes enactment of Medicaid expansion.

Supplement Figure 2. Mean quarterly number of Medicaid financed patients in thousands treated with buprenorphine in expansion states by age group, 2012-18




Data Source: 2012-2018 IQVIA LRx . Vertical line denotes enactment of Medicaid expansion.

Supplement Figure 3: Mean quarterly number of Medicaid financed patients in thousands treated with buprenorphine in non-expansion states by age group, 2012-18




Data Source: 2012-2018 IQVIA LRx. Vertical line denotes enactment of Medicaid expansion.

Supplement Figure 4: Total mean quarterly number of privately insured patients in thousands treated with buprenorphine in expansion and non-expansion states, 2012-18



Data source: 2012-2018 IQVIA LRx. Vertical line denotes enactment of Medicaid expansion.

Supplement Figure 5: Total mean quarterly number of other publicly insured* patients in thousands treated with buprenorphine in expansion and non-expansion states, 2012-18



Data source: 2012-2018 IQVIA LRx data. *Excludes Medicaid insured patients.